Patents by Inventor Jane Anne Healy

Jane Anne Healy has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST AND LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF FOR TREATING PATIENTS WITH CANCER
    Publication number: 20240010729
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1), a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and lenvatinib or a pharmaceutically acceptable salt thereof and the use of the combination therapies for the treatment cancer.
    Type: Application
    Filed: September 14, 2021
    Publication date: January 11, 2024
    Inventors: Jane Anne Healy, Sujata Shrawankuma Jha, Patricia Marinello, Rodolfo Fleury Perini, Jaqueline Willemann Rogerio
  • METHODS FOR TREATING CANCER OR INFECTION USING A COMBINATION OF AN ANTI-PD-1 ANTIBODY, AN ANTI-CTLA4 ANTIBODY, AND AN ANTI-TIGIT ANTIBODY
    Publication number: 20230092707
    Abstract: Provided herein are methods of treating a cancer, an infectious disease or infection, which comprise administering to a subject in need thereof a combination of agents: (a) an anti-human PD-1 antibody or antigen binding fragment thereof; (b) an anti-human CTLA4 antibody or antigen binding fragment thereof; and (c) an anti-human TIGIT antibody or antigen binding fragment thereof. Also provided are therapeutic combinations for use, pharmaceutical compositions and kits containing such agents for the treatment of a cancer, an infectious disease, or an infection.
    Type: Application
    Filed: March 4, 2021
    Publication date: March 23, 2023
    Applicant: MERCK SHARP & DOHME LLC
    Inventors: Rachel A. Altura, Mingmei Cai, Scott J. Diede, Jane Anne Healy, Blanca Homet Moreno, Nageatte Ibrahim, Sybil M.G. Williams
  • DOSING REGIMEN OF ANTI-TIGIT ANTIBODY FOR TREATMENT OF CANCER
    Publication number: 20210403557
    Abstract: The present invention relates to dosing regimens of an anti-TIGIT antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an anti-TIGIT antibody.
    Type: Application
    Filed: November 4, 2019
    Publication date: December 30, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Mingmei Cai, Elliot K. Chartash, Jane Anne Healy, Mallika Lala, Tommy Ruosi Li, Kapil Mayawala, Raluca Andreia Predoiu, Sybil M.G. Williams, Zhen Zeng
  • DOSING REGIMEN OF ANTI-LAG3 ANTIBODY AND COMBINATION THERAPY WITH ANTI-PD-1 ANTIBODY FOR TREATING CANCER
    Publication number: 20210347889
    Abstract: The present invention relates to dosing regimens of an anti-LAG3 antibody useful for the treatment of cancer. In particular, the invention relates to the dosing regimen in a combination therapy which comprises administering an antibody of a Programmed Death 1 protein (PD-1) or Programmed Death Ligand 1 (PD-L1) and an antibody of Lymphocyte-Activation Gene 3 (LAG3). The invention also provides a method for treating cancer in a patient comprising administering to the patient an anti-LAG3 antibody and an anti-PD-1 antibody, wherein the tumor tissue section of the patient is PD-L 1 expression positive, and optionally LAG3 expression positive.
    Type: Application
    Filed: November 4, 2019
    Publication date: November 11, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Anson Kunjachan Abraham, Elliot K. Chartash, Kenneth Emancipator, Rosario Garrido, Jane Anne Healy, Jonathan W. Juco, Diane Levitan, Qing Zhao
  • COMBINATION THERAPY OF A PD-1 ANTAGONIST AND LAG3 ANTAGONIST FOR TREATING PATIENTS WITH NON-MICROSATELLITE INSTABILITY-HIGH OR PROFICIENT MISMATCH REPAIR COLORECTAL CANCER
    Publication number: 20210317214
    Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a Lymphocyte-Activation Gene 3 (LAG3) antagonist, and the use of the combination therapies for the treatment of non-microsatellite instability-high (non-MSI-H) or proficient mismatch repair (pMMR) colorectal cancer.
    Type: Application
    Filed: September 9, 2019
    Publication date: October 14, 2021
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Elliot K. Chartash, Terrill K. McClanahan, Jane Anne Healy